Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Inv. presentation
|
|
Outlook Therapeutics, Inc. (ONS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/06/2023 |
4
| Gangolli Julian S (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 370,282 options to buy
@ $0.24, valued at
$88.9k
|
|
| 10/05/2023 |
4
| Haller Julia A (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 210,225 options to buy
@ $0.24, valued at
$50.5k
|
|
| 10/05/2023 |
4
| Huang Andong (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 191,113 options to buy
@ $0.24, valued at
$45.9k
|
|
| 10/05/2023 |
4
| Auffarth Gerd (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 210,225 options to buy
@ $0.24, valued at
$50.5k
|
|
| 10/05/2023 |
4
| Haddadin Yezan Munther (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 358,337 options to buy
@ $0.24, valued at
$86k
|
|
| 10/05/2023 |
4
| Sukhtian Faisal Ghiath (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 372,671 options to buy
@ $0.24, valued at
$89.4k
|
|
| 10/05/2023 |
4
| HILZINGER KURT J (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 286,670 options to buy
@ $0.24, valued at
$68.8k
|
|
| 08/25/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/14/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results|
Docs:
|
"Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones · Prescription Drug User Fee Act goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration ISELIN, N.J., August 14, 2023 — Outlook Therapeutics, Inc. , a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of wet AMD, today announced recent corporate highlights and financial results for its fiscal third quarter ended June 30, 2023. Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, commented, “We continue to be focused on our pre-launch activi..." |
|
| 05/16/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits... |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/15/2023 |
8-K
| Quarterly results |
| 04/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/03/2023 |
8-K/A
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 03/31/2023 |
4
| Haddadin Yezan Munther (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 41,065 options to buy
@ $1.05, valued at
$43.1k
|
|
| 03/31/2023 |
4
| Haller Julia A (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 41,065 options to buy
@ $1.05, valued at
$43.1k
|
|
| 03/31/2023 |
4
| Huang Andong (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 41,065 options to buy
@ $1.05, valued at
$43.1k
|
|
| 03/31/2023 |
4
| Auffarth Gerd (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 41,065 options to buy
@ $1.05, valued at
$43.1k
|
|
| 03/31/2023 |
4
| Gangolli Julian S (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 41,065 options to buy
@ $1.05, valued at
$43.1k
|
|
| 03/31/2023 |
4
| Sukhtian Faisal Ghiath (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 41,065 options to buy
@ $1.05, valued at
$43.1k
|
|
| 03/31/2023 |
4
| THURMAN RANDY H (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 41,065 options to buy
@ $1.05, valued at
$43.1k
|
|
| 03/31/2023 |
4
| HILZINGER KURT J (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 41,065 options to buy
@ $1.05, valued at
$43.1k
|
|
| 02/14/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/14/2023 |
8-K
| Quarterly results |
| 01/27/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 01/24/2023 |
4
| Evanson Jeff (Chief Commercial Officer) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Sold 267,000 shares
@ $1.11, valued at
$296.4k
|
|
| 01/24/2023 |
10-K/A
| Annual Report for the period ended September 30, 2022 [amend] |
| 01/19/2023 |
4
| Evanson Jeff (Chief Commercial Officer) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Sold 27,162 shares
@ $1.31, valued at
$35.6k
Sold 33,738 shares
@ $1.25, valued at
$42.2k
Sold 103,255 shares
@ $1.22, valued at
$126k
|
|
|
|
|